Allopurinol improves endothelial function and reduces oxidant-inflammatory enzyme of myeloperoxidase in metabolic syndrome

Basit Öğe Kaydı
dc.authorid0000-0002-2858-4023en_US
dc.authorid0000-0002-5634-1280en_US
dc.authorid0000-0003-1407-5313en_US
dc.authorid0000-0002-0709-5415en_US
dc.authorid0000-0001-7444-6193en_US
dc.contributor.authorYiğiner, Ömer
dc.contributor.authorÖzçelik, Fatih
dc.contributor.authorİnanç, Tuğrul
dc.contributor.authorAparcı, Mustafa
dc.contributor.authorÖzmen, Namık
dc.contributor.authorKardeşoğlu, Ejder
dc.contributor.authorSüleymanoğlu, Selami
dc.contributor.authorŞener, Göksel
dc.contributor.authorCebeci, Bekir Sıtkı
dc.date.accessioned2024-07-12T21:03:03Z
dc.date.available2024-07-12T21:03:03Z
dc.date.issued2008en_US
dc.departmentFakülteler, Tıp Fakültesien_US
dc.description.abstractObjective In this study, we tested in patients with metabolic syndrome whether allopurinol through decreasing oxidative stress improves endothelial function, and ameliorates inflammatory state represented by markers of myeloperoxidase, C-reactive protein (CRP) and fibrinogen. Methods In a randomized, double-blind fashion; subjects with metabolic syndrome were treated with allopurinol (n = 28) or placebo (n = 22) for one month. Before and after treatment, blood samples were collected and the flow-mediated dilation (FMD) and isosorbide dinitrate (ISDN)-mediated dilation of the brachial artery were performed. Results Baseline clinical characteristics of the allopurinol and placebo groups demonstrated no differences in terms of clinical characteristics, endothelial function and inflammatory markers. After the treatment with allopurinol, FMD was increased from 8.0 ± 0.5 % to 11.8 ± 0.6% (P < 0.01), but there were no change in the placebo group. In both groups, ISDN-mediated dilation is unaffected by the treatment. As a marker of oxidative stress, allopurinol significantly reduced malondialdehyde. Moreover, myeloperoxidase levels were reduced by the treatment with allopurinol (56.1 ± 3.4 ng/ml vs. 44.4 ± 2.4 ng/ml, P < 0.05) but there were no change in the placebo group. Surprisingly, neither CRP nor fibrinogen levels were affected by the treatment in both groups. Conclusion Xanthine oxidoreductase inhibition by allopurinol in patients with metabolic syndrome reduces oxidative stress, improves endothelial function, ameliorates myeloperoxidase levels and does not have any effect on CRP and fibrinogen levels.en_US
dc.identifier.citationYiginer, O., Ozcelik, F., Inanc, T., Aparci, M., Ozmen, N., Cingozbay, B. Y., Kardesoglu, E., Suleymanoglu, S., Sener, G. ve Cebeci, B. S. (2008). Allopurinol improves endothelial function and reduces oxidant-inflammatory enzyme of myeloperoxidase in metabolic syndrome. Clinical research in cardiology, Springerlink. 97(5), 334–340.en_US
dc.identifier.endpage340en_US
dc.identifier.issn1861-0684
dc.identifier.issn1861-0692
dc.identifier.issue5en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage334en_US
dc.identifier.urihttps://link.springer.com/article/10.1007/s00392-007-0636-3
dc.identifier.urihttps://hdl.handle.net/20.500.12415/3624
dc.identifier.volume97en_US
dc.institutionauthorCingözbay, Bekir Yılmaz
dc.language.isoenen_US
dc.publisherSpringerlinken_US
dc.relation.ispartofClinical Research in Cardiologyen_US
dc.relation.isversionof10.1007/s00392-007-0636-3en_US
dc.relation.publicationcategoryUluslararası Hakemli Dergide Makale - Kurum Öğretim Elemanıen_US
dc.rightsCC0 1.0 Universal*
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rights.urihttp://creativecommons.org/publicdomain/zero/1.0/*
dc.snmzKY00539
dc.subjectmetabolic syndromeen_US
dc.subjectallopurinolen_US
dc.subjectmyeloperoxidaseen_US
dc.subjectendothelial dysfunctionen_US
dc.subjectC-reactive proteinen_US
dc.titleAllopurinol improves endothelial function and reduces oxidant-inflammatory enzyme of myeloperoxidase in metabolic syndromeen_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

Tıp Fakültesi Koleksiyonu